| Background: NR6A1/CT150,as an orphan receptor,is a novel member of the cancer-testis antigen(CT)family.Here,we investigated the expression and function of NR6A1 and its underlying mechanisms in prostate cancer(PCa)patients who underwent radical prostatectomy.Methods: NR6A1 mRNA expression was examined by employing reverse transcriptase-polymerase chain reaction(RT-PCR).A total of 303 prostate cancer after radical prostatectomy were analysed in a tissue microarray(TMA)for NR6A1immunohistochemistry-based protein expression.Kaplan–Meier/log-rank analysis and Cox regression analysis were used to investigate the relationship between NR6A1 expression and clinicopathological factors in PCa.Small interfering RNA mediated gene silencing approach was used to knockdown NR6A1 to investigate its potential role in prostate cancer cells.Results: NR6A1 mRNA expression was 31.25%(5/16)and protein expression was29.7%(90/303)in PCa patients.NR6A1 expression was significantly associated with Gleason score(GS)(P=0.003)and tumor stage(P=0.042).The patients with positive NR6A1 expression have a shorter biochemical recurrence-free survival.NR6A1 predicted biochemical recurrence in univariate(P=0.0159)and multivariate models(P=0.0317).In addition,gene silencing of NR6A1 resulted in G0/G1 phase cell cycle arrest,and decreased metastatic and invasive potential of prostate cancer cells DU145 and PC3.In addition,down regulation of NR6A1 could reverse Epithelial-to-mesenchymal transition(EMT)process.Conclusions: NR6A1 played a prominent role in migration and invasion of PCa cells,and indicated that NR6A1 may act as a novel marker for biochemical recurrence after radical prostatectomy. |
